[(2R,3R,4R,5R)-4-fluoro-4-methyl-5-(4-methyl-2-oxopyrimidin-1-yl)-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: [(2R,3R,4R,5R)-4-fluoro-4-methyl-5-(4-methyl-2-oxopyrimidin-1-yl)-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
• 化学式: C₁₉H₂₇FN₂O₆
• 分子量: 398.4
• InChiKey: OAVBXHPQUCHLLB-BCXHYRKLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  94.5
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
  申请人：Carroll Steven S.

  公开号：US20140328799A1

  公开（公告）日：2014-11-06

  The present invention is directed to compositions comprising inhibitors of hepatitis C virus (HCV) protease and one or more additional therapeutically effective agents. Uses of such compositions as HCV inhibitors and methods of treating infection by HCV by administration of such compositions are also disclosed.
• SUBSTITUTED NUCLEOTIDE ANALOGS
  申请人：Alios BioPharma, Inc.

  公开号：US20150038451A1

  公开（公告）日：2015-02-05

  Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs.
• US8772474B2
  申请人：——

  公开号：US8772474B2

  公开（公告）日：2014-07-08
• US8871737B2
  申请人：——

  公开号：US8871737B2

  公开（公告）日：2014-10-28
• US9278990B2
  申请人：——

  公开号：US9278990B2

  公开（公告）日：2016-03-08